Condition: Human Papilloma Virus · Anal Dysplasia · HIV · Sponsor: University of Maryland, Baltimore
This is a phase 2, open-label study to assess the immunogenicity of the 9-valent human papillomavirus (HPV) recombinant vaccine (Gardasil9) in people born male with current or past exposure to androgen blockers or estrogen (BM-EABE). Investigators will enroll BM-EABE with HIV and HIV negative controls (BM-EABE or men who have sex with a person with a penis (MSPP)) and administer Gardasil9 at timepoints Day 0, Month 2, and Month 6. The immune response to the vaccine will be analyzed at Month 7 (1 month following the final vaccine dose).
This description comes directly from the study's public registry record.
Omar Harfouch, MD · 410-706-1372 · oharfouch@ihv.umaryland.edu
Onyinyechi Ogbumbadiugha-Weekes, MPH · 443-635-4943 · oogbumbadiugha@ihv.umaryland.edu
Always discuss trial participation with your own doctor first.
| RIIS Clinic at HIPS | Washington D.C., District of Columbia, United States | Not Yet Recruiting |
| RIIS Clinic at Baltimore Safe Haven | Baltimore, Maryland, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06624839